We have six clinical-phase development projects and six projects in discovery or pre-clinical development. Our projects comprise two clinical oncology projects (Sym004 and Sym015) and three oncology discovery projects targeting FLT3 (Sym027), AXL (Sym028) and CD40 (Sym029). We are advancing three immuno-oncology targets through phase 1 (Sym021-Sym023) and three projects are in discovery or pre-clinical development (Sym024-Sym026). Finally, one clinical infectious disease project (Sym009) is being developed by Genentech. Status and future plans are outlined in this pipeline section.
We believe, that our clinical programs are well-suited for combination or stand-alone therapies.
We target some of the largest epithelial cancer indications, such as colorectal and lung cancers.
The partnered clinical-stage projects are an immuno-oncology program of six targets being developed in collaboration with Servier, three of which are in Phase 1 development, and a project directed to Staphylococcus aureus bacteremia, which is in Phase 1 development by Genentech.
In addition to our clinical trials, we maintain extensive proprietary and partnered discovery and preclinical activities to continue to realize the potential of our technology platform.
What are antibodies?
Antibodies are Y-shaped proteins produced by specialized cells of the body’s immune system. Antibodies can identify and bind disease-specific antigens found on bacteria, viruses, and cancer cells. Once attached to the antigen, antibodies can recruit other parts of the immune system to help neutralize the cells containing the antigen. The place on the antigen where the antibody binds is called an epitope. Researchers can design antibodies to target a certain antigen. Antibodies can be made in large amounts known as monoclonal antibodies (mAbs). Monoclonal antibodies are a well-established drug class today used to treat many diseases, including cancer.